Rational approach to an antiprion compound with a multiple mechanism of action

Future Medicinal Chemistry

Volumn 7, Issue 16, 2015, Pages 2113-2120

  Bolognesi, Maria Laura ^a   Bongarzone, Salvatore ^b   Aulic, Suzana ^c   Ai Tran, Hoang Ngoc ^d   Prati, Federica ^a   Carloni, Paolo ^e,f   Legname, Giuseppe ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c SISSA   (Italy)

^d UNIVERSITY OF CALGARY   (Canada)

^e Institute of Advanced Simulation ^*  (Germany)

^f RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

7 CHLOROQUINOLINE; 8 QUINOLINOL; ANTIPRION COMPOUND; BICAPPA; CENTRAL NERVOUS SYSTEM AGENTS; CHELATING AGENT; PRION PROTEIN; QUINOLINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; LIGAND; ORGANOMETALLIC COMPOUND; PRION;

ANTIOXIDANT ACTIVITY; ANTIPRION ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; EC50; IN VITRO STUDY; LC50; NEUROTOXICITY; OXIDATIVE STRESS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN MOTIF; SCRAPIE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; METABOLISM; PRION; PRION DISEASES; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

DRUG DESIGN; HUMANS; LIGANDS; ORGANOMETALLIC COMPOUNDS; OXYQUINOLINE; PRION DISEASES; PRIONS; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84947565434     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.79     Document Type: Article

References (45)

1. Prusiner SB. Molecular biology of prion diseases. Science 252(5012), 1515-1522 (1991).
2. Winklhofer KF, Tatzelt J, Haass C. The two faces of protein misfolding: gain-and loss-of-function in neurodegenerative diseases. EMBO J. 27(2), 336-349 (2008).
3. Prusiner SB. Cell biology. A unifying role for prions in neurodegenerative diseases. Science 336(6088), 1511-1513 (2012).
4. Ashe KH, Aguzzi A. Prions, prionoids and pathogenic proteins in Alzheimer disease. Prion 7(1), 55-59 (2013).
5. Chen B, Thompson M, Louth J, Guo K. Prion chemical biology: on the road to therapeutics? Curr. Top Med. Chem.13(19), 2441-2464 (2013).
6. Geschwind MD, Kuo AL, Wong KS et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology 81(23), 2015-2023 (2013).
7. Stoilova T, Colombo L, Forloni G, Tagliavini F, Salmona M. A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J. Med. Chem. 56(15), 5987 (2013).
8. Forloni G, Salmona M, Marcon G, Tagliavini F. Tetracyclines and prion infectivity. Infect. Disord. Drug. Targets. 9(1), 23-30 (2009).
9. Forloni G, Iussich S, Awan T et al. Tetracyclines affect prion infectivity. Proc. Natl Acad. Sci. USA 99(16), 10849-10854 (2002).
10. Haik S, Marcon G, Mallet A et al. Doxycycline in Creutzfeldt-Jakob disease: A Phase 2, randomised, double-blind, placebocontrolled trial. Lancet Neurol. 13(2), 150-158 (2014).
11. Bolognesi ML, Legname G. Approaches for discovering antiprion compounds: lessons learned and challenges ahead. Expert Opin. Drug Discov. 10(4), 389-97 (2015).
12. Gaggelli E, Kozlowski H, Valensin D, Valensin G. Copper homeostasis and neurodegenerative disorders (Alzheimer's, prion, and Parkinson's diseases and amyotrophic lateral sclerosis). Chem. Rev. 106(6), 1995-2044 (2006).
13. Brown DR, Guantieri V, Grasso G, Impellizzeri G, Pappalardo G, Rizzarelli E. Copper(II) complexes of peptide fragments of the prion protein. Conformation changes induced by copper(II) and the binding motif in C-terminal protein region. J. Inorg. Biochem. 98(1), 133-143 (2004).
14. Lehmann S. Metal ions and prion diseases. Curr. Opin. Chem. Biol. 6(2), 187-192 (2002).
15. Gasperini L, Meneghetti E, Pastore B, Benetti F, Legname G. Prion protein and copper cooperatively protect neurons by modulating nmda receptor through S-nitrosylation. Antioxid. Redox Sign. 22(9), 772-784 (2015).
16. Singh N, Singh A, Das D, Mohan ML. Redox control of prion and disease pathogenesis. Antioxid. Redox Sign. 12(11), 1271-1294 (2010).
17. Soto C, Satani N. The intricate mechanisms of neurodegeneration in prion diseases. Trends Mol. Med. 17(1), 14-24 (2010).
18. Cavalli A, Bolognesi ML, Minarini A et al. Multi-targetdirected ligands to combat neurodegenerative diseases. J. Med. Chem. 51(3), 347-372 (2008).
19. Bolognesi ML. Polypharmacology in a single drug: multitarget drugs. Curr. Med. Chem. 20(13), 1639-1645 (2013).
20. Bongarzone S, Staderini M, Bolognesi ML. Multitarget ligands and theranostics: sharpening the medicinal chemistry sword against prion diseases. Future Med. Chem. 6(9), 1017-1029 (2014).
21. Morphy R. Selective multitargeted drugs. In: Polypharmacology in Drug Discovery. Peters J-U (Ed.). John Wiley & Sons, Inc., NJ, USA, 245-262 (2012).
22. Morphy JR, Harris CJ. Designing Multi-Target Drugs. Royal Society of Chemistry, RSC drug discovery, Cambridge, UK (2012).
23. Bongarzone S, Bolognesi ML. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. Expert Opin. Drug Discov. 6(3), 251-268 (2011).
24. Torrent J, Vilchez-Acosta A, Munoz-Torrero D et al. Interaction of prion protein with acetylcholinesterase: potential pathobiological implications in prion diseases. Acta Neuropathol. Commun. 3(1), 18 (2015).
25. Prachayasittikul V, Prachayasittikul S, Ruchirawat S, Prachayasittikul V. 8-Hydroxyquinolines: A review of their metal chelating properties and medicinal applications. Drug Des. Devel. Ther. 7, 1157-1178 (2013).
26. Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits betaamyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30(3), 665-676 (2001).
27. Ritchie CW, Bush AI, Mackinnon A et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot Phase 2 clinical trial. Arch. Neurol. 60(12), 1685-1691 (2003).
28. LeVine H, 3rd, Ding Q, Walker JA, Voss RS, Augelli-Szafran CE. Clioquinol and other hydroxyquinoline derivatives inhibit Abeta(1-42) oligomer assembly. Neurosci. Lett. 465(1), 99-103 (2009).
29. Adlard PA, Cherny RA, Finkelstein DI et al. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59(1), 43-55 (2008).
30. Gal S, Fridkin M, Amit T, Zheng H, Youdim MB. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidaseab inhibitory activity for Parkinson's disease. J. Neural. Transm. 70(Suppl.), 447-456 (2006).
31. Pollera C, Lucchini B, Formentin E, Bareggi S, Poli G, Ponti W. Evaluation of anti-prionic activity of clioquinol in an in vivo model (Mesocricetus auratus). Vet. Res. Commun. 29(Suppl. 2), 253-255 (2005).
32. Song Yn, Xu H, Chen W, Zhan P, Liu X. 8-Hydroxyquinoline: A privileged structure with a broadranging pharmacological potential. Med. Chem. Comm. 6(1), 61-74 (2015).
33. Fernandez-Bachiller MI, Perez C, Gonzalez-Munoz GC et al. Novel tacrine-8-hydroxyquinoline hybrids as multifunctional agents for the treatment of Alzheimer's disease, with neuroprotective, cholinergic, antioxidant, and copper-complexing properties. J. Med. Chem. 53(13), 4927-4937 (2010).
34. Antequera D, Bolos M, Spuch C et al. Effects of a tacrine-8-hydroxyquinoline hybrid (IQM-622) on a beta accumulation and cell death: involvement in hippocampal neuronal loss in Alzheimer's disease. Neurobiol. Dis. 46(3), 682-691 (2012).
35. Bongarzone S, Tran HN, Cavalli A et al. Parallel synthesis, evaluation, and preliminary structure-activity relationship of 2,5-diamino-1,4-benzoquinones as a novel class of bivalent anti-prion compound. J. Med. Chem. 53(22), 8197-8201 (2010).
36. Bongarzone S, Tran HN, Cavalli A et al. Hybrid lipoic acid derivatives to attack prion disease on multiple fronts. Chem. Med. Chem. 6(4), 601-605 (2011).
37. Natarajan JK, Alumasa JN, Yearick K et al. 4-N-, 4-S-, and 4-O-chloroquine analogues: influence of side chain length and quinolyl nitrogen pKa on activity vs chloroquine resistant malaria. J. Med. Chem. 51(12), 3466-3479 (2008).
38. May BC, Fafarman AT, Hong SB et al. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines. Proc. Natl Acad. Sci. USA 100(6), 3416-3421 (2003).
39. Tran HN, Bongarzone S, Carloni P, Legname G, Bolognesi ML. Synthesis and evaluation of a library of 2,5-bisdiamino-benzoquinone derivatives as probes to modulate protein-protein interactions in prions. Bioorg. Med. Chem. Lett. 20(6), 1866-1868 (2010).
40. Bolognesi ML, Ai Tran HN, Staderini M et al. Discovery of a class of diketopiperazines as antiprion compounds. Chem. Med. Chem. 5(8), 1324-1334 (2010).
41. Staderini M, Aulić S, Bartolini M et al. A Fluorescent styrylquinoline with combined therapeutic and diagnostic activities against Alzheimer's and prion diseases. ACS Med. Chem. Lett. 4(2), 225-229 (2012).
42. Colby DW, Zhang Q, Wang S et al. Prion detection by an amyloid seeding assay. Proc. Natl Acad. Sci. USA 104(52), 20914-20919 (2007).
43. Milhavet O, McMahon HE, Rachidi W et al. Prion infection impairs the cellular response to oxidative stress. Proc. Natl Acad. Sci. USA 97(25), 13937-13942 (2000).
44. Petersen RB, Siedlak SL, Lee HG et al. Redox metals and oxidative abnormalities in human prion diseases. Acta Neuropathol. 110(3), 232-238 (2005).
45. Ghaemmaghami S, Ahn M, Lessard P et al. Continuous quinacrine treatment results in the formation of drugresistant prions. PLoS Pathog. 5(11), e1000673 (2009).